Objective To clinically, genetically, and radiologically characterize a large cohort of SPG7 patients.
Results
We identified 42 cases with biallelic SPG7 mutations, including 7 novel mutations, including a large multi-exon deletion, representing one of the largest cohorts so far described. We identified a characteristic phenotype comprising cerebellar ataxia with prominent cerebellar dysarthria, mild lower limb spasticity, and a waddling gait, predominantly from a cohort of idiopathic ataxia. We report a rare brain MRI finding of dentate nucleus hyperintensity on T2 sequences with SPG7 mutations. We confirm that the c.1529C>T allele is frequently present in patients with longstanding British ancestry. Based on the findings of the present study and existing literature, we confirm that patients with homozygous mutations involving the M41 peptidase domain of SPG7 have a younger age at onset compared to individuals with mutations elsewhere in the gene (14 years difference, p < 0.034), whereas c.1529C>T compound heterozygous mutations are associated with a younger age at onset compared to homozygous cases (5.4 years difference, p < 0.022).
Conclusions
Mutant SPG7 is common in sporadic ataxia. In patients with British ancestry, c.1529C>T allele represents the most frequent mutation. SPG7 mutations can be clinically predicted by the characteristic hybrid spastic-ataxic phenotype described above, along with T2 hyperintensity of the dentate nucleus on MRI.
Hereditary spastic paraplegia (HSP) and hereditary cerebellar ataxias (HCA) are heterogeneous groups of progressive neurodegenerative conditions with considerable overlap. 1, 2 HSP is complicated when features such as ataxia, neuropathy, optic atrophy, and weakness are present. 3 HCA can also be associated with spastic paraplegia. There are over 80 different genetic loci associated with HSP and similar number associated with cerebellar ataxias. [4] [5] [6] This extensive genetic heterogeneity together with the overlapping features of HCA and complicated HSP often causes difficulties in disease classification and clinical approach to genetic diagnosis.
Next-generation sequencing (NGS) gene panels are available for both HSP and HCA patients. However, such panel tests are expensive and not always readily available. Our objective was to describe clinical, genetic, and radiologic features of a British cohort of SPG7 cases where the phenotype may be helpful in providing guidance to targeted genetic testing. We highlight the importance of such clinical characterization through our experience of diagnosing a large cohort of patients with mutations in the SPG7 gene, implicated in both HSP and HCA. 7 In addition, by reviewing all published SPG7 mutation data, we make important new genotype-phenotype correlations.
Methods

Patient cohorts
We studied all cases positive for SPG7 mutation in our HSP and ataxia cohorts, which mainly include patients from the North of England (cohort study) and analyzed all clinical, genetic, and neuroimaging data.
Standard protocol approvals, registrations
Patient consent was obtained for genetic testing in accordance with the departmental regulations. Healthy control cases for MRI were recruited as per ethics committee approval (REC reference 09/H1310/79, IRAS 26259). STROBE checklist for cohort study adhered in reporting the data.
Genetic testing
Libraries of sheared genomic DNA corresponding to panels of either HCA or HSP genes captured using a SureSelect XT custom designed probe set (Agilent, Cheadle, UK), and pairend sequenced using a HiSeq 2500 instrument (Illumina) was used. Raw data were analyzed using the Genome Analysis ToolKit, 8 (Broad Institute, Cambridge, MA) according to guidelines. 9, 10 After initial identification of 11 patients with SPG7 mutations using the ataxia and HSP gene panels, we evaluated the phenotype to identify a triad of spastic paraplegia (usually mild), cerebellar ataxia (with prominent cerebellar dysarthria), and waddling gait indicative of proximal muscle weakness. Thereafter, the majority of patients who presented who had the above triad were analyzed by bidirectional Sanger sequencing and dosage analysis (multiplex ligation-dependent probe amplification kit P213-B1 and B2, MRC-Holland) of all 17 exons of the SPG7 gene. The remainder of the cohort were identified using either HSP or HCA gene panel testing as before.
Chromatographs were analyzed using Mutation surveyor v4.0.8 (softgenetics.com). Annotation of mutations was carried out in accordance with Human Genome Variation society nomenclature (hgvs.org/mutnomen), with nomenclature based on the reference sequence NM_003119.3. Novel variants in the SPG7 gene were assessed for pathogenicity using Alamut Visual version 2.9.0 (Interactive Biosoftware, Rouen, France) and prediction software (Provean, MutPred, SNPS & GO and PolyPhen2). Allele frequencies for novel variants in normal control populations were obtained from the Genome Aggregation Database (gnomAD).
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Neuroimaging MRIs, available for all patients who underwent MRI, were analyzed for cerebellar atrophy. Further subanalysis of the dentate nucleus was undertaken for all patients who underwent brain imaging on the same 3-T MR scanner (Ingenia, Philips Medical Systems, Eindhoven, The Netherlands) using the same T2-weighted sequence (avoid machine-related variability) (cases: n = 21 and controls: n = 16). This was compared with age-and sex-matched controls imaged with this sequence. The axial T2-weighted parameters were as follows: repetition time 3,000 ms, time to echo 80, echo train length 15, number of averages was 1 and 4 mm thick, 512 × 512 matrix. Matching criteria for healthy controls were age within 3 years and sex. Relative signal intensity of the dentate nucleus was compared to normal-appearing pontine white matter and red nucleus. A region of interest (area 20 mm 2 ) in these structures was placed in the region of the dentate nucleus with the lowest signal. The dentate nucleus signal was then dichotomized by whether the ratio of the signals was less than or more than 1 (i.e., hypointense or hyperintense compared to normalappearing white matter in the pons).
Literature review
Two clinicians independently reviewed clinical and genetic details of all SPG7 cases thus far reported in the literature (until September 30, 2017). We searched the following terms in PubMed, MEDLINE, Web of Science, and Embase: SPG7, paraplegin, hereditary spastic paraparesis, HSP (mutations), spastic ataxia, and ataxia, and selected all the articles reporting SPG7 and/or paraplegin mutations and reviewed the phenotype and genotype data published. We excluded publications that were not in English or where English translation was not Glossary DN = dentate nuclei; HCA = hereditary cerebellar ataxias; HSP = hereditary spastic paraplegia; NGS = Next-generation sequencing; PEO = Progressive external ophthalmoplegia; RN = red nuclei; SARA = Scale for the assessment and rating of ataxia. available and articles that did not describe clinical features. All mutations described by us and previously reported are depicted in a schematic diagram in relation to functionally important domains ( figure 1 ) (e-table 1, links.lww.com/NXG/A89).
Statistical analyses
Statistical analysis was performed using Prism GraphPad V7.0b and SPSS (2015) statistical software programs. Oneway analysis of variance was used for multiple group comparisons, and independent samples t test and χ 2 test were used to compare 2 groups.
Data availability
All anonymized data can be shared on a collaborative basis.
Results
Characterization of the phenotype
We identified a total of 42 cases positive for pathogenic mutations in both alleles of the SPG7 gene (table 1) . Initially, 11 cases were identified using ataxia or HSP NGS gene panels (4 patients using ataxia panel and 7 patients using the HSP panel). On reviewing the phenotype of these 11 cases, we noted that 9 individuals had cerebellar ataxia with prominent slurring of speech, mild spasticity, and proximal muscle weakness resulting in a waddling gait.
Direct genetic screening based on the phenotype Following the clinical characterization of the initial 11 patients, we undertook direct testing for mutations in the SPG7 gene in patients who demonstrated the above phenotype in a cohort of patients attending the Sheffield Ataxia Centre and HSP clinics. We identified a further 27 cases with pathogenic mutations (table 1) . Four other cases were already diagnosed when referred to us (panel tests).
The clinical characteristics of the 42 probands are summarized in table 2. There was no history of consanguinity. Eighty-three percent were male. The average age of symptom onset was 41.7 years (SD: ± 11, median age 44 years). Female patients developed symptoms on average 4 years earlier than male patients (38.5 vs 42.5 years) (table 2). The mean duration of disease at the time of diagnosis was 9.6 years (SD: ±5.2, mode 5). Thirty-eight of 42 patients (90%) were of long-standing British ancestry. Four were UK citizens of Indian, Iranian, German, and Bulgarian descent.
Ninety-eight percent of cases presented with gait unsteadiness followed by dysarthric speech (76%). Thirty-two patients (76%) complained of mild spasticity. Two patients presented with the typical spastic gait characteristic of HSP (5%) and 7 patients (16%) presented with moderate-to-severe spasticity. Seventy-six percent (32 of 42) had mildly increased lower limb tone and 93% had brisk reflexes, while the Babinski sign was positive in 51%.
At baseline, 38 patients (90%) were found to have at least some evidence of cerebellar ataxia and 33 (79%) were found to have both mild spasticity and cerebellar ataxia. Despite the cerebellar features, only 2 cases were nonambulant, with a total symptomatic disease duration of 399 patient-years. None of the 
when compared to spino cerebellar ataxia 6 (median score 15.0) for the same duration of symptoms.
Sixty-four percent of cases demonstrated the triad of cerebellar ataxia with dysarthria, spasticity, and waddling gait at presentation, and 9 others developed the full clinical picture during follow-up (totaling 87%). Progressive external ophthalmoplegia (PEO) was observed only in 1 patient. Another patient had vertical gaze palsy. Nystagmus was present in 38% of patients. Optic atrophy was seen in 1 patient. Waddling gait was seen in 87% of our cases.
Although 4 patients were found to have reduced vibration sense and 3 had reduced pinprick sensation on clinical examination, none of the 19 patients who underwent neurophysiologic assessment had evidence of large fiber peripheral neuropathy or myopathy.
Mutation analysis
Fifteen cases (36%) were homozygous for mutations in the SPG7 gene, while 27 cases (64%) were compound heterozygous. Twelve of the 15 homozygous cases had the common missense mutation in exon 11, c.1529C>T, p. In addition, to the single case with a large deletion, several small insertions, duplications, deletions, and splice site mutations were detected on 7 alleles, 5 of which have been previously described. Most of the pathogenic alleles were missense mutations (63 of 84) while 21 were nonsense mutations (table 1) .
Novel mutations in SPG7
We discovered 7 novel likely pathogenic mutations in the SPG7 gene (table 1) del) was identified using multiplex ligation-dependent probe amplification. One of the novel missense mutation, c.1373C>T, p.(Ala458Val), results in substitution of a conserved amino acid, which is proven to be deleterious using in silico analysis while found in one allele in gnomAD database supporting pathogenicity. The second missense mutation c.2083C>G, p.(Leu695Val) resulted in substitution of the same amino acid as a previously reported pathogenic mutation c.2084T>C, p.(Leu695Pro). 12 Predictions by PROVEAN (deleterious), PolyPhen2 (probably damaging), and MutPred (actionable figure 2, A and B) . T1 sequences of both dentate nuclei (DN) and the red nuclei (RN) were not distinguishable between controls and SPG7 cases ( figure 2, A and C) . The same T2 sequence on 3-T imaging was available in 21 patients and these were matched with 17 healthy controls. In the 16 healthy controls, the DN were hypointense compared to normal-appearing white matter (figure 2C), and 1 healthy control had DN isointense relative to normal-appearing white matter. The DN were isointense or hyperintense compared with normal-appearing white matter (T2 imaging) in 18 of the 21 SPG7-positive cases ( figure 2D ). Both controls and patients showed no difference in the appearance of the RN, which were hypointense compared to normal-appearing white matter in the pons ( figure 2E ). The increase in DN T2 hyperintensity on MRI in SPG7 cases was significant compared to the controls (χ 2 test value 25.76, at p < 0.001) (figure 2F).
Genotype-phenotype correlation from current and other studies We analyzed mutations in the different functionally important domains of SPG7 shown in figure 1 for any impact on age at onset of symptoms. Patients who had homozygous mutation in the M41 peptidase domain had an earlier onset of disease symptoms (by 12 years) compared to patients with mutations in a nonfunctionally assigned domain (p < 0.022) ( figure 3A) . Having homozygous, compound heterozygous mutations or the presence of null alleles did not have an impact on age at onset. However, we also noted that patients with the c.1529C>T mutation when in a compound-heterozygote state developed symptoms 8 years earlier compared to c.1529C>T homozygous cases (p < 0.019, unpaired t test) (figure 3B).
Discussion
We describe a large British cohort of 42 unrelated and previously unreported cases with mutations in the SPG7 gene. The largest other single-center cohort so far reported is a Dutch cohort of 46 unrelated families. 13 We propose that the phenotype of cerebellar ataxia (with marked dysarthria), mild lower limb spasticity, and waddling gait is clinically distinct and should alert clinicians to direct genetic testing for SPG7. Such an approach identified 64% of our cohort. While SPG7 biallelic mutations have historically been associated with HSP, it is now clear that ataxia is the major clinical presentation, as only 26% of our cohort presented with an HSP-like phenotype. 7, 14, 15 In another UK-based study, SPG7 accounted for 18.6% of 70 patients with unexplained ataxia and pyramidal signs.
7 SPG7 is the fourth commonest cause of any genetic ataxia in the United Kingdom and the second commonest recessive ataxia. 16 In
Only 2 patients were wheelchair-dependent, indicating that ambulatory loss appears to be rare in SPG7 cases, 15 with an average SARA score of 8 (range: 3.5-14). This favorable prognostic factor will be useful when counseling SPG7 patients and their families.
A considerable proportion of our cohort was male (83%). Female patients tended to develop symptoms about 4 years earlier.
The median age at onset of symptoms was 44 years, indicating that SPG7-related disease is a late-onset disease in keeping with previous reports. 13, 17 The age at onset, however, did range between 15 and 60 years; therefore, SPG7 can rarely present with an early-onset ataxia. The recessive inheritance accounts for the lack of a positive family history. Absence of a family history should therefore not deter clinicians from SPG7 testing.
PEO was only seen in one of our patients but has been reported in 11% of SPG7 cases worldwide. A previous report found that 13% of the patients with PEO have SPG7. PEO was also reported in 1 of 5 cases in a UK cohort of complex HSP. 18 Overall, PEO in SPG7 was also rare in other cohorts, including a French (2/23), 19 a Dutch (2/46), 13 and a French Canadian cohort (none of the 22 individuals). 15 A longitudinal study of SPG7 patients from the United Kingdom reported a median follow-up duration of 23 years from presentation to detecting PEO, 7 as did a Norwegian group (median follow-up of 24 years). 20 Clinicians should be aware that PEO-like features in SPG7 are rare but can develop late in the disease process.
Optic neuropathy was reported in 9.5% of the worldwide SPG7 cases, compared to one patient in our cohort. In a French cohort of SPG7 patients, 44% had evidence of optic neuropathy based on optical coherence tomography, yet 40% of the patients with optic neuropathy had normal-appearing optic discs on funduscopy. It is therefore likely that optic atrophy is common in SPG7-mutated patients but the clinical significance of this remains unclear.
SPG7 cases have mild cerebellar atrophy and none had severe atrophy (table 2). The increased T2 signal from the dentate nucleus in SPG7 cases compared to controls has not been previously reported. The dentate nucleus is a site of iron accumulation in normal aging, and this is usually associated with reduced T2 signal. The high signal noted in SPG7 cases does not appear to be due to a globally reduced brain iron accumulation. In support of the MRI findings are postmortem data from an SPG7 case, which showed neuronal loss in the dentate nucleus. 21 While the above imaging finding is not specific for SPG7 mutations, yet it is an important characteristic and merits further consideration. 22 We propose that dentate nucleus hyperintensity on MRI T2 sequences, without severe overlying cerebellar atrophy and in the context of a typical phenotype, aid the diagnosis of mutant SPG7.
We also discovered 8 cases heterozygous for SPG7 (SPG7-Het) (50% were c.1529C>T). As the pathogenicity of the SPG7-Het is not well established, we have not included further analysis. However, analysis of the MRI appearances showed 2 of 8 SPG7-Hets had T2 hyperintensity of the DN (e-table 2, links.lww.com/NXG/A90).
The association of waddling gait has not been previously highlighted in relation to SPG7. There are a number of reports describing muscle weakness over and above the mild pyramidal weakness seen in patients with HSP. 19 In keeping with our observations, myopathic features were noted in a PEO cohort. 17 Furthermore, two-thirds of the SPG7 cases from the Dutch cohort were noted to have lower limb muscle weakness. 13 This weakness may account for the rationale of performing muscle biopsies in some cases that have, on occasions, shown evidence of mitochondrial dysfunction. 14, 19, 23, 24 More than 242 cases of SPG7 have been described worldwide. Analysis of the mutations demonstrates unique genotype- phenotype correlations in SPG7, wherein mutations in the M41 peptidase domain are associated with younger age at onset and c.1529C>T homozygous mutations tend to associate with later onset of disease compared to compound heterozygotes. Further studies are needed to confirm above findings.
We identified 7 novel mutations, 70% resulting in premature truncation of the paraplegin protein. The c.1529C>T mutation was present in at least one allele in all patients with British ancestry, strongly supporting a previous report of its association with patients with British heritage. 14 We observed that c.1529C>T is the commonest mutant SPG7 allele worldwide, and this allele frequency in our cohort was 60%. The c.1454_1462del mutation is the second most common mutation (9%).
We have highlighted that SPG7 is a common cause of sporadic ataxia. We recommend direct genetic testing for SPG7 mutations when cerebellar ataxia with dysarthria is associated with mild lower limb spasticity and a waddling gait. If the patient is of long-standing British ancestry, directly testing for the c.1529C>T mutation is highly likely to be diagnostic. The MRI feature of relative T2 hyperintensity of the DN is also strongly supportive of mutant SPG7. 
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